147 related articles for article (PubMed ID: 35418220)
1. PEN2: Metformin's new partner at lysosome.
Sakamoto K; Jessen N
Cell Res; 2022 Jun; 32(6):507-508. PubMed ID: 35418220
[No Abstract] [Full Text] [Related]
2. A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate.
McCarty MF
Med Hypotheses; 1999 Feb; 52(2):89-93. PubMed ID: 10340287
[TBL] [Abstract][Full Text] [Related]
3. Low-dose metformin targets the lysosomal AMPK pathway through PEN2.
Ma T; Tian X; Zhang B; Li M; Wang Y; Yang C; Wu J; Wei X; Qu Q; Yu Y; Long S; Feng JW; Li C; Zhang C; Xie C; Wu Y; Xu Z; Chen J; Yu Y; Huang X; He Y; Yao L; Zhang L; Zhu M; Wang W; Wang ZC; Zhang M; Bao Y; Jia W; Lin SY; Ye Z; Piao HL; Deng X; Zhang CS; Lin SC
Nature; 2022 Mar; 603(7899):159-165. PubMed ID: 35197629
[TBL] [Abstract][Full Text] [Related]
4. Regulation of organelle function by metformin.
Kim J; You YJ
IUBMB Life; 2017 Jul; 69(7):459-469. PubMed ID: 28444922
[TBL] [Abstract][Full Text] [Related]
5. High dose targeted delivery on cancer sites and the importance of short-chain fatty acids for metformin's action: Two crucial aspects of the wonder drug.
Maniar K; Singh V; Chakrabarti A; Bhattacharyya R; Banerjee D
Regul Toxicol Pharmacol; 2018 Aug; 97():15-16. PubMed ID: 29857113
[TBL] [Abstract][Full Text] [Related]
6. Multidimensional mechanisms of metformin in cancer treatment.
Singh-Makkar S; Pandav K; Hathaway D; Paul T; Youssef P
Tumori; 2022 Apr; 108(2):111-118. PubMed ID: 34139918
[TBL] [Abstract][Full Text] [Related]
7. miR-378a-3p Participates in Metformin's Mechanism of Action on C2C12 Cells under Hyperglycemia.
Machado IF; Teodoro JS; Castela AC; Palmeira CM; Rolo AP
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430391
[TBL] [Abstract][Full Text] [Related]
8. Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity.
Xie F; Ke AB; Bowers GD; Zamek-Gliszczynski MJ
J Pharmacol Exp Ther; 2015 Aug; 354(2):225-9. PubMed ID: 26062557
[TBL] [Abstract][Full Text] [Related]
9. The 120-minute oral glucose tolerance test is sufficient for the evaluation of metformin's glucose-lowering effect in healthy volunteers.
Cho S; Son H; Cho SK
Int J Clin Pharmacol Ther; 2018 Mar; 56(3):151-154. PubMed ID: 29319500
[No Abstract] [Full Text] [Related]
10. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.
Gong J; Kelekar G; Shen J; Shen J; Kaur S; Mita M
Target Oncol; 2016 Aug; 11(4):447-67. PubMed ID: 26864078
[TBL] [Abstract][Full Text] [Related]
11. Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux.
Tai S; Sun J; Zhou Y; Zhu Z; He Y; Chen M; Yang H; Xiao Y; Tu T; Tang L; Li X; Zeng J; Zheng X; Zhou S
J Adv Res; 2022 Nov; 41():205-218. PubMed ID: 36328749
[TBL] [Abstract][Full Text] [Related]
12. Metformin and Angiogenesis in Cancer - Revisited.
Kannarkatt J; Alkharabsheh O; Tokala H; Dimitrov NV
Oncology; 2016; 91(4):179-184. PubMed ID: 27487294
[TBL] [Abstract][Full Text] [Related]
13. Metformin - its potential anti-cancer and anti-aging effects.
Podhorecka M; Ibanez B; Dmoszyńska A
Postepy Hig Med Dosw (Online); 2017 Mar; 71(0):170-175. PubMed ID: 28258677
[TBL] [Abstract][Full Text] [Related]
14. Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
Ahmed ZSO; Golovoy M; Abdullah Y; Ahmed RSI; Dou QP
Recent Pat Anticancer Drug Discov; 2021; 16(2):161-186. PubMed ID: 34132186
[TBL] [Abstract][Full Text] [Related]
15. Low-dose metformin and PEN2-dependent lysosomal AMPK activation: benefits outnumber side effects.
Liu L; Patnana PK; Nimmagadda SC
Signal Transduct Target Ther; 2022 Jun; 7(1):178. PubMed ID: 35661690
[No Abstract] [Full Text] [Related]
16. Metformin prevents BAFF activation of Erk1/2 from B-cell proliferation and survival by impeding mTOR-PTEN/Akt signaling pathway.
Chen X; Ma J; Yao Y; Zhu J; Zhou Z; Zhao R; Dong X; Gao W; Zhang S; Huang S; Chen L
Int Immunopharmacol; 2021 Jul; 96():107771. PubMed ID: 34004440
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Jaromy M; Miller JD
Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
[TBL] [Abstract][Full Text] [Related]
18. Metformin prevents the pathological browning of subcutaneous white adipose tissue.
Auger C; Knuth CM; Abdullahi A; Samadi O; Parousis A; Jeschke MG
Mol Metab; 2019 Nov; 29():12-23. PubMed ID: 31668383
[TBL] [Abstract][Full Text] [Related]
19. [Metformin's effect on 5-fluorouracil,cisplatin,paclitaxel in laryngocarcinoma Hep-2 cells].
Zhou CY; Li XM; Shan S; Jia LF; Huang ZL
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Apr; 31(7):524-528. PubMed ID: 29871302
[No Abstract] [Full Text] [Related]
20. Metformin adapts its cellular effects to bioenergetic status in a model of metabolic dysfunction.
Auger C; Sivayoganathan T; Abdullahi A; Parousis A; Pang BW; Jeschke MG
Sci Rep; 2018 Apr; 8(1):5646. PubMed ID: 29618839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
